Quantifying Viable M. tuberculosis Safely Obviating the Need for High Containment Facilities.
Accessibility
Containment level III
Diagnosis
GTC
Heat inactivation
TB-MBLA
Tuberculosis
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
ppublish
Résumé
Mycobacterium tuberculosis is an infectious pathogen that requires biosafety level-3 laboratory for handling. The risk of transmission is high to laboratory staff, and to manage the organism safely, it is necessary to construct high containment laboratory facilities at great expense. This limits the application of tuberculosis diagnostics to areas where there is insufficient capital to invest in laboratory infrastructure. In this method, we describe a process of inactivating sputum samples by either heat or guanidine thiocyanate (GTC) that renders them safe without affecting the quantification of viable bacteria. This method eliminates the need for level 3 containment laboratory for the tuberculosis molecular bacterial load assay (TB-MBLA) and is applicable in low- and middle-income countries.
Identifiants
pubmed: 38949708
doi: 10.1007/978-1-0716-3981-8_14
doi:
Substances chimiques
Thiocyanates
0
guanidine thiocyanate
593-84-0
Guanidines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-152Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lange C, Aarnoutse R, Chesov D, van Crevel R, Gillespie SH, Grobbel HP et al (2020) Perspective for precision medicine for tuberculosis. Front Immunol 11:566608
Siddiqi SH, Rüsch-Gerdes S (2006) MGIT Procedure Manual: For BACTEC™ MGIT 960™ TB System. 2006;(July):1–52
World Health Organization (2021) Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), 1–86 p
World Health Organisation (2022) Global tuberculosis report. Geneva
Joshi R, Reingold AL, Menzies D, Pai M (2006) Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med 3(12):2376–2391
doi: 10.1371/journal.pmed.0030494
World Health Organization (2012) Tuberculosis laboratory biosafety manual. World Health Organization Publication. ISBN 978 92 41504638, Geneva
Allen V, Nicol MP, Tow LA (2016) Sputum processing prior to mycobacterium tuberculosis detection by culture or nucleic acid amplification testing: a narrative review. Res Rev J Microbiol Biotechnol 5(1):96–108
Mtafya B, Qwaray P, John J, Sichone E, Shoo A, Gillespie SH et al (2023) A practical approach to render tuberculosis samples safe for application of tuberculosis molecular bacterial load assay in clinical settings without a biosafety level 3 laboratory. Tuberculosis 138(November 2022):102275
doi: 10.1016/j.tube.2022.102275
pubmed: 36434867
Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R et al (2020) Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay. Thorax 75:606–608
doi: 10.1136/thoraxjnl-2019-214238
pubmed: 32354738
Ntinginya NE, Bakuli A, Mapamba D, Sabiiti W, Kibiki G, Minja LT et al (2022) Tuberculosis molecular bacterial load assay reveals early delayed bacterial killing in patients with relapse. Clin Infect Dis 76(3):990–994
doi: 10.1093/cid/ciac445